Pfizer scrambles to reassure investors on RA drug deaths

Heading into the Easter weekend Pfizer ($PFE) had to scramble to try and contain the damage from a report published online that four people had died and another four developed infections after taking the company's closely-watched rheumatoid arthritis drug tofacitinib. Widely considered one of the big pharma company's top late-stage drug prospects, the news instantly went viral and took a three percent bite out of Pfizer's shares.

In a research report, Wells Fargo analyst Larry Biegelsen noted that an abstract on a clinical trial of tofacitinib outlined the four deaths, noting that there was no clear explanation of what caused the deaths. As Pfizer shares swooned, the company quickly hustled out a release explaining that only one of the four deaths, triggered by respiratory failure, was drug related.

"The mortality rate from all causes across the tofacitinib RA development program, including the ORAL Sync study, is within the range of rates reported for biologic therapies for RA," Pfizer stated.

After a string of high-profile Phase III failures, Pfizer badly needs a big win. And with analysts enthusiastic about a potential mega-billion dollar market for tofacitinib, the experimental drug offers Pfizer one of only a few near-term possible pipeline victories. But the FDA has been particularly sensitive to cardio safety issues in recent years, which could pose a key threat to the program.

"Now that you're doing longer trials and you see some deaths, the cardiovascular scrutiny here is going to be really tight because the FDA obviously doesn't want another Vioxx issue," Hapoalim Securities analyst Jon Lecroy tells Reuters.

"It's a big overreaction," CLSA analyst David Maris told Bloomberg. Investors "saw four deaths and flipped out, and as they start to digest this a little more they'll realize it doesn't appear to be as bad as people thought."

- read the Pfizer release
- see the Reuters story
- and here's the report from Bloomberg

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.